Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).

person Suzanne Trudel Princess Margaret Cancer Centre, Toronto, ON, Canada info_outline Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir I. Vorobyev, Michele Cavo, Kazuhito Suzuki, Pawel Robak, Kristin Morris, Amy Phillips-Jones, Xiaoou Linnette Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos

Authors person Suzanne Trudel Princess Margaret Cancer Centre, Toronto, ON, Canada info_outline Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir I. Vorobyev, Michele Cavo, Kazuhito Suzuki, Pawel Robak, Kristin Morris, Amy Phillips-Jones, Xiaoou Linnette Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos Organizations Princess Margaret Cancer Centre, Toronto, ON, Canada, Ankara University, Ankara, Turkey, University Hospital Brno, Brno, Czech Republic, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia, Leningrad Regional Clinical Hospital, Saint-Petersburg, Russian Federation, Università di Bologna, Bologna, Italy, The Jikei University School of Medicine, Tokyo, Japan, Medical University of Lodz, Lodz, Poland, GSK plc, Philadelphia, PA, GSK plc, London, United Kingdom, GlaxoSmithKline (GSK), Waltham, MA, GSK, Waltham, MA, GSK, Upper Providence, PA, Glaxo Smith Kline, Upper Providence, PA, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Salamanca, Spain, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece Abstract Disclosures

Clinical